ATROVENT HFA Drug Patent Profile
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
When do Atrovent Hfa patents expire, and what generic alternatives are available?
Atrovent Hfa is a drug marketed by Boehringer Ingelheim and is included in one NDA. There is one patent protecting this drug.
This drug has ten patent family members in nine countries.
The generic ingredient in ATROVENT HFA is ipratropium bromide. There are eight drug master file entries for this compound. Sixteen suppliers are listed for this compound. Additional details are available on the ipratropium bromide profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Atrovent Hfa
A generic version of ATROVENT HFA was approved as ipratropium bromide by RITEDOSE CORP on January 26th, 2001.
Summary for ATROVENT HFA
| International Patents: | 10 |
| US Patents: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 14 |
| Clinical Trials: | 47 |
| Patent Applications: | 5,451 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for ATROVENT HFA |
| Drug Sales Revenues: | Drug sales revenues for ATROVENT HFA |
| DailyMed Link: | ATROVENT HFA at DailyMed |
See drug prices for ATROVENT HFA
Recent Clinical Trials for ATROVENT HFA
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Hat Yai Medical Education Center | Phase 3 |
| Nationwide Children's Hospital | Phase 4 |
| University of Nevada, Las Vegas | Phase 4 |
Pharmacology for ATROVENT HFA
| Drug Class | Anticholinergic |
| Mechanism of Action | Cholinergic Antagonists |
Anatomical Therapeutic Chemical (ATC) Classes for ATROVENT HFA
US Patents and Regulatory Information for ATROVENT HFA
ATROVENT HFA is protected by one US patents.
Patents protecting ATROVENT HFA
Inhaler device
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Boehringer Ingelheim | ATROVENT HFA | ipratropium bromide | AEROSOL, METERED;INHALATION | 021527-001 | Nov 27, 2004 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for ATROVENT HFA
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Boehringer Ingelheim | ATROVENT HFA | ipratropium bromide | AEROSOL, METERED;INHALATION | 021527-001 | Nov 27, 2004 | ⤷ Try a Trial | ⤷ Try a Trial |
| Boehringer Ingelheim | ATROVENT HFA | ipratropium bromide | AEROSOL, METERED;INHALATION | 021527-001 | Nov 27, 2004 | ⤷ Try a Trial | ⤷ Try a Trial |
| Boehringer Ingelheim | ATROVENT HFA | ipratropium bromide | AEROSOL, METERED;INHALATION | 021527-001 | Nov 27, 2004 | ⤷ Try a Trial | ⤷ Try a Trial |
| Boehringer Ingelheim | ATROVENT HFA | ipratropium bromide | AEROSOL, METERED;INHALATION | 021527-001 | Nov 27, 2004 | ⤷ Try a Trial | ⤷ Try a Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for ATROVENT HFA
See the table below for patents covering ATROVENT HFA around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| World Intellectual Property Organization (WIPO) | 2009037085 | ⤷ Try a Trial | |
| Bulgaria | 62382 | ⤷ Try a Trial | |
| Hungary | 0201330 | ⤷ Try a Trial | |
| Poland | 205866 | ⤷ Try a Trial | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2023 - 2024
NCE-1 Patent Challenge Dates 2023 - 2024
DrugChatter - AI-based answers to questions about drugs
RxJam - Trigger-based marketing for life sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2023, www.DrugPatentWatch.com.
Follow DrugPatentWatch:
